Literature DB >> 20685933

Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection.

Hanna Dreja1, Eithne O'Sullivan, Corinna Pade, Kelli M Greene, Hongmei Gao, Keith Aubin, James Hand, Are Isaksen, Carl D'Souza, Werner Leber, David Montefiori, Michael S Seaman, Jane Anderson, Chloe Orkin, Aine McKnight.   

Abstract

The array of human immunodeficiency virus (HIV) subtypes encountered in East London, an area long associated with migration, is unusually heterogeneous, reflecting the diverse geographical origins of the population. In this study it was shown that viral subtypes or clades infecting a sample of HIV type 1 (HIV-1)-positive individuals in East London reflect the global pandemic. The authors studied the humoral response in 210 treatment-naïve chronically HIV-1-infected (>1 year) adult subjects against a panel of 12 viruses from six different clades. Plasmas from individuals infected with clade C, but also plasmas from clade A, and to a lesser degree clade CRF02_AG and CRF01_AE, were significantly more potent at neutralizing the tested viruses compared with plasmas from individuals infected with clade B. The difference in humoral robustness between clade C- and B-infected patients was confirmed in titration studies with an extended panel of clade B and C viruses. These results support the approach to develop an HIV-1 vaccine that includes clade C or A envelope protein (Env) immunogens for the induction of a potent neutralizing humoral response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685933     DOI: 10.1099/vir.0.024224-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.

Authors:  Gama P Bandawe; Penny L Moore; Lise Werner; Elin S Gray; Daniel J Sheward; Maphuti Madiga; Andile Nofemela; Ruwayhida Thebus; Jinny C Marais; Leonard Maboko; Salim S Abdool Karim; Michael Hoelscher; Lynn Morris; Carolyn Williamson
Journal:  J Infect Dis       Date:  2014-11-14       Impact factor: 5.226

2.  Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.

Authors:  Rajeev Gautam; Yoshiaki Nishimura; Wendy R Lee; Olivia Donau; Alicia Buckler-White; Masashi Shingai; Reza Sadjadpour; Stephen D Schmidt; Celia C LaBranche; Brandon F Keele; David Montefiori; John R Mascola; Malcolm A Martin
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 3.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.

Authors:  Masashi Shingai; Olivia K Donau; Stephen D Schmidt; Rajeev Gautam; Ronald J Plishka; Alicia Buckler-White; Reza Sadjadpour; Wendy R Lee; Celia C LaBranche; David C Montefiori; John R Mascola; Yoshiaki Nishimura; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-05       Impact factor: 11.205

5.  Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120.

Authors:  Julie Matz; Pascal Kessler; Jérôme Bouchet; Olivier Combes; Oscar Henrique Pereira Ramos; Francis Barin; Daniel Baty; Loïc Martin; Serge Benichou; Patrick Chames
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

6.  The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.

Authors:  Antoine Chaillon; Thierry Wack; Martine Braibant; Laurent Mandelbrot; Stéphane Blanche; Josiane Warszawski; Francis Barin
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

7.  Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.

Authors:  Samir K Lakhashe; Vijayakumar Velu; Gaia Sciaranghella; Nagadenahalli B Siddappa; Janet M Dipasquale; Girish Hemashettar; John K Yoon; Robert A Rasmussen; Feng Yang; Sandra J Lee; David C Montefiori; Francis J Novembre; François Villinger; Rama Rao Amara; Maria Kahn; Shiu-Lok Hu; Sufen Li; Zhongxia Li; Fred R Frankel; Marjorie Robert-Guroff; Welkin E Johnson; Judy Lieberman; Ruth M Ruprecht
Journal:  Vaccine       Date:  2011-07-14       Impact factor: 3.641

8.  CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants.

Authors:  Hanna Dreja; Corinna Pade; Lei Chen; Áine McKnight
Journal:  J Gen Virol       Date:  2015-03-11       Impact factor: 3.891

9.  Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection.

Authors:  Samir K Lakhashe; Wendy Wang; Nagadenahalli B Siddappa; Girish Hemashettar; Patricia Polacino; Shiu-Lok Hu; François Villinger; James G Else; Francis J Novembre; John K Yoon; Sandra J Lee; David C Montefiori; Ruth M Ruprecht; Robert A Rasmussen
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

10.  Disease Progression in HIV-1-Infected Viremic Controllers.

Authors:  Katherine C Groves; David F Bibby; Duncan A Clark; Are Isaksen; Jane R Deayton; Jane Anderson; Chloe Orkin; Andrew J Stagg; Aine McKnight
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.